Company intelligence / Profile preview

HEM Pharma Inc.

Pohang-si, Gyeongbuk, South Koreahempharma.bio ↗

Ownership: Private
Development stage: Phase 2

Overview

HEMP-002 (LARS treatment) has received approval from Australian HREC for Phase 2 IND based on safety profile. HEMP-001 (depression treatment) was approved by the FDA for Phase 2 IND based on safety profile, including suppressing inflammation and improving serotonin levels.

Therapeutic areas: GastroenterologyPsychiatryMetabolic Disorders
Modalities: Live Biotherapeutic Products (LBP)
Industry: Biotech

Drug pipeline

1 asset

HEM1036

Unknown

Partnerships

Amway Korea

Beyond the preview

Go deeper on HEM Pharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEM Pharma Inc..

Explore the full profile